Could China’s New GLP-1 Drugs Beat Out Ozempic?  Scientific American

As GLP-1 medications including Wegovy, Ozempic, Mounjaro and Zepbound reshape diabetes and weight loss care, recent developments such as new partnerships, safety questions and challenges in patient persistence show the

Innovent Biologics Inc. announced June 27 that it gained National Medical Products Administration’s (NMPA) approval of mazdutide as a new weight loss therapy for obese or overweight patients in China.

Post Content

Aims/hypothesis: Growing evidence implicates gut microbiota-derived metabolites in metabolic homeostasis. Indole, a microbial tryptophan metabolite, has been reported to enhance Glucagon-like peptide-1 (GLP-1) secretion in vitro, and its derivatives have

Hollywood’s upper crust has converged on Venice for the three-day wedding extravaganza of Amazon mogul Jeff Bezos and Lauren Sanchez, with a cluster of snatched waists drawing attention and fueling

A federal judge said the government did not run afoul of the law when it required Johnson & Johnson to seek approval before implementing its proposed 340B rebate model. The

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Novo Nordisk markets its semaglutide drugs as Ozempic pre-filled pens

With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to reap

Imagine getting rid of your persistent fat layers, while gaining girth down under. That’s a contemporary equivalent to the fabled fountain of youth, and a special class of weight loss

Amgen AMGN is one of the several drug makers racing to develop the next blockbuster weight loss drug and take a share of the booming weight loss drug market. The obesity

Post Content

GLP-1 drugs, such as Ozempic, are reshaping diabetes care and weight loss. Find out if Medicare covers them and if they’re right for you.

Innovent said on Friday that its obesity medicine mazdutide has been approved in China, becoming the first dual GLP-1/glucagon agonist to be greenlit for the disease anywhere in the world.

GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have led to hospitalisations and even deaths.

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials. Drugs like Wegovy and Mounjaro – or diabetes

Shares in Amylyx Pharmaceuticals (NASDAQ: AMLX) were up almost 28% in the week to Friday morning. The move comes after an analyst at Guggenheim initiated coverage of the small-cap stock

Shares in Amylyx Pharmaceuticals (NASDAQ: AMLX) were up almost 28% in the week to Friday morning. The move comes after an analyst at Guggenheim initiated coverage of the small-cap stock

Novo Nordisk’s Pricing Crossroads: Regulatory Risks and Competitive Pressures Threaten GLP-1 Dominance  AInvest

A WOMAN has revealed that thanks to Mounjaro, she has lost eight stone and has dropped from a size 20 to an 8. But Alexandra, 33, who is from the

Semaglutide is linked to a reduced risk for Alzheimer’s disease-related dementia in patients with diabetes vs other antidiabetic drugs, a new study suggests. Medscape Medical News

Weight-loss drugs are this decade’s blockbuster medicines. Drugs like Ozempic, Wegovy, and Mounjaro help people with diabetes get their blood sugar under control and help overweight and obese people reach

Since the GLP-1 drugs, including Mounjaro, Ozempic and Wegovy, were licensed, there have been hundreds of reported cases of acute and chronic pancreatitis among people taking them, figures from the

Some cases of pancreatitis have been reported to be linked to GLP-1 medicines. Here’s what we know

Women on Mounjaro may miss signs of pancreatitis. Learn the symptoms, risks, and what UK health authorities are doing to monitor GLP-1 weight loss drugs.

The weight-loss injection boom that swept through Hollywood and boardrooms alike is now facing a potentially deadly reckoning. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a

The United Kingdom’s health regulator is investigating weight loss jabs like Ozempic and Mounjaro after linking it to hundreds of severe illnesses and even a handful of deaths. As the

GLP-1 has become a hot topic in health and wellness. If you’ve heard of medications like Ozempic or Wegovy, then you’ve already heard about GLP-1. These drugs work by mimicking

The UK’s MHRA and Genomics England have launched a groundbreaking study to investigate whether genetics play a role in developing acute pancreatitis after taking GLP-1 weight-loss drugs like Ozempic, Mounjaro,

What does the fracturing of vaccine advice and policy mean for the U.S. health care ecosystem? Will the potential head of the Centers for Disease Control and Prevention stand up

This week German startup Climatiq secured $11.7m to embed carbon intelligence into daily business operations and Turkish farm digitization startup Doktar secured $8.8m to expand AI-driven agtech globally. Elsewhere, PepsiCo

Viking Therapeutics VKTX announced that it has initiated the phase III VANQUISH program, evaluating the subcutaneous (SC) formulation of its experimental obesity drug VK2735 in adult patients with or without type

Weight loss and diabetes jabs taken by more than a million people in Britain have been linked to a potential serious side effect, with some deaths, according to data from

GLP-1 agonists were linked to greater risk for neovascular age-related macular degeneration.

After three years, only about 1 in 12 individuals taking GLP-1s to treat obesity remained on the therapy, according to a Prime Therapeutics study published on June 25. Prime is

Eli Lilly LLY has experienced significant growth in the past few years, particularly driven by the success of its popular tirzepatide injections, Mounjaro for type II diabetes (T2D) and Zepbound

Merck MRK has built a substantial portfolio of new products and pipeline candidates in areas like oncology, vaccines, neuroscience, and infectious disease. Merck’s phase III pipeline has almost tripled since 2021,

Over 100 cases of acute pancreatitis have been reported to UK health regulators this year, many tied to the newest GLP-1 drug on the market.

There are serious potential side effects to GLP-1 weight-loss drugs. This episode features audio from: https://nutritionfacts.org/video/is-ozempic-semaglutide-safe-does-it-increase-cancer-risk/ Visit the video page for all sources and doctor’s notes related to this podcast.

Drs. Idries and Jamil Abdur-Rahman answer medical questions about the health effects of drinking instant coffee, the possibility of GLP-1 medications increasing the risk of dementia, and pregnancy diets on

It’s taken me a couple of months to get to this but a reader in Montreal wanted to be sure I did not miss this article: Twinkies’ New Owner Courts

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we uncover the extent of low-quality generic cancer

GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro and Wegovy 

FAT jabs have been linked to hundreds of people falling sick and some dying from an organ-destroying illness, the UK’s drug watchdog has warned. Brits have reported falling seriously ill with pancreatitis, a

Eli Lilly is set to launch Mounjaro in KwikPen, a user-friendly, prefilled pen for weekly administration, in India, following regulatory approval. This offers a convenient option for adults with type

Some cases of pancreatitis have been reported to be linked to GLP-1 medicines. Here’s what we know

NEW DELHI: India’s drug regulator has approved Eli Lilly and Company’s diabetes and obesity drug Mounjaro in a KwikPen presentation, the pharmaceutical giant announced on Thursday. The Central Drugs Standard

Some cases of pancreatitis have been reported to be linked to GLP-1 medicines. Here’s what we know

My weight has always been the one thing I had felt in control of, since I was a teenager. All it took was a little willpower, even after two pregnancies,

Hundreds of weight loss and diabetes jab users have reported problems with their pancreas, with some cases proving fatal, according to new data. Data from the medicines regulator shows that

I really think big pharma was behind the whole fat acceptance movement. Obesity has sky rocketed over the last few decades, alongside big pharma profits. It’s like the whole saying

Since the GLP-1 drugs, including Mounjaro, Ozempic and Wegovy, were licensed, there have been hundreds of reported cases of acute and chronic pancreatitis among people taking them, figures from the

Some people may be at more risk from bad reactions due to their genes (Picture: Getty) Hundreds of people have reported problems with their pancreas after taking weight loss drugs,

THERE ARE NEWER DRUGS ON THE WAY THAT DON’T TO THIS: Studies exploring muscle loss from GLP-1 drugs. I’d like to see a medication that combines fat loss with myostatin

UK health officials launch study into side-effects of weight loss drugs after increased reports of acute pancreatitis Hundreds of people have reported problems with their pancreas linked to taking weight

We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will summarize the bull’s thesis on NVO. Novo Nordisk A/S’s share was

Originally designed to treat type 2 diabetes, GLP-1 medications like Ozempic and Wegovy quickly made it into the hands of every now-formerly hefty person in your life. A new study

The market for weight-loss drugs continues to grow, but the competition for the largest share of this expanding “pie” is intense. The American pharmaceutical giant Eli Lilly and Co. is

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful treatment for obesity. With just a once-monthly shot of ‘MariTide,’

The J. M. Smucker Company (NYSE:SJM) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 Stocks. The J. M. Smucker Company (NYSE:SJM)

How did Novo Nordisk get to the position it’s in now — with its stock halved over the past year and the company widely seen as trailing Eli Lilly in

In this podcast, Motley Fool Chief Investment Officer Andy Cross and contributors Jason Hall and Matt Frankel discuss: Fair Isaac Corp. to include buy now, pay later data. The importance

Studies on stem cell therapy, GLP-1 drugs, and a new infusion pump are discussed by Professor Diener in this update on movement disorders. Medscape Neurology

A Shanghai-based biotech, previously known as a generics and manufacturing player, posted mid-stage results suggesting its incretin drug might be one of the most powerful to have reached the clinic.

Post Content